About: Therapy of small cell lung cancer with emphasis on oral topotecan

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Therapy of small cell lung cancer with emphasis on oral topotecan Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Systemic chemotherapy plays the major role in the management of patients with small cell lung cancer. Cisplatin plus etoposide is the most widely used regimen and is considered as standard in patients with limited disease. Cisplatin plus irinotecan improved survival compared to cisplatin plus etoposide in a Japanese trial but failed to do so in two trials in Caucasians. Cisplatin plus topotecan had similar efficacy compared to cisplatin plus etoposide in patients with extensive disease. In the second-line setting, topotecan showed similar efficacy but better tolerability compared to cyclophosphamide, doxorubin plus vincristine. Oral topotecan was as efficacious as its intravenous formulation and was shown to improve survival compared to best supportive care alone in patients previously treated with chemotherapy. Thus topotecan is considered as the standard second-line chemotherapy in patients with small cell lung cancer. Systemic chemotherapy plays the major role in the management of patients with small cell lung cancer. Cisplatin plus etoposide is the most widely used regimen and is considered as standard in patients with limited disease. Cisplatin plus irinotecan improved survival compared to cisplatin plus etoposide in a Japanese trial but failed to do so in two trials in Caucasians. Cisplatin plus topotecan had similar efficacy compared to cisplatin plus etoposide in patients with extensive disease. In the second-line setting, topotecan showed similar efficacy but better tolerability compared to cyclophosphamide, doxorubin plus vincristine. Oral topotecan was as efficacious as its intravenous formulation and was shown to improve survival compared to best supportive care alone in patients previously treated with chemotherapy. Thus topotecan is considered as the standard second-line chemotherapy in patients with small cell lung cancer. (en)
Title	Therapy of small cell lung cancer with emphasis on oral topotecan Therapy of small cell lung cancer with emphasis on oral topotecan (en)
skos:prefLabel	Therapy of small cell lung cancer with emphasis on oral topotecan Therapy of small cell lung cancer with emphasis on oral topotecan (en)
skos:notation	RIV/00216224:14110/10:00051508!RIV12-MSM-14110___
http://linked.open...avai/riv/aktivita	I V
http://linked.open...avai/riv/aktivity	I, V
http://linked.open...iv/cisloPeriodika	1
http://linked.open...vai/riv/dodaniDat	2012
http://linked.open...aciTvurceVysledku	Skřičková, Jana
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykova univerzita / Lékařská fakulta
http://linked.open...dnocenehoVysledku	292688
http://linked.open...ai/riv/idVysledku	RIV/00216224:14110/10:00051508
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Chemotherapy; New drugs; Thoracic radiotherapy; Brain irradiation; Second-line therapy; Topotecan (en)
http://linked.open.../riv/klicoveSlovo	Brain irradiation Second-line therapy Thoracic radiotherapy New drugs Topotecan Chemotherapy
http://linked.open...odStatuVydavatele	IE - Irsko
http://linked.open...ontrolniKodProRIV	[75EA72309A21]
http://linked.open...i/riv/nazevZdroje	Lung Cancer
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	16 (xsd:int)
http://linked.open...UplatneniVysledku	2010
http://linked.open...v/svazekPeriodika	70
http://linked.open...iv/tvurceVysledku	Skřičková, Jana Pirker, Robert Berzinec, Peter Brincat, S. Kasan, P. Ostoros, G. Pesek, M. Plate, S. Purkalne, G. Rooneem, R. Stanculeanu, D. Timcheva, C. Tzekova, V. Zakotnik, B. Zielinski, Ch.C. Zwitter, M.
http://linked.open...ain/vavai/riv/wos	000282503700002
issn	0169-5002
number of pages	7 (xsd:int)
http://bibframe.org/vocab/doi	10.1016/j.lungcan.2010.05.020
http://localhost/t...ganizacniJednotka	14110
is http://linked.open...avai/riv/vysledek of	Therapy of small cell lung cancer with emphasis on oral topotecan Therapy of small cell lung cancer with emphasis on oral topotecan

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 38 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software